Drug Profile
4D 110
Alternative Names: 4D-110; 4D-R110; RG 6247Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator 4D Molecular Therapeutics
- Developer 4D Molecular Therapeutics; Roche
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Choroideraemia
Most Recent Events
- 02 Aug 2023 4D 110 is still in phase I trial for Choroideraemia in the US (4D Molecular Therapeutics pipeline, July 2023)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Choroideraemia in USA (Intravitreous)
- 31 Dec 2022 4D Molecular Therapeutics completes enrolment in its Phase-I clinical trials in Choroideraemia in USA (Intravitreous) before December 2022